Logo image of CGEM

CULLINAN THERAPEUTICS INC (CGEM) Stock Fundamental Analysis

USA - NASDAQ:CGEM - US2300311063 - Common Stock

5.95 USD
+0.2 (+3.48%)
Last: 10/3/2025, 11:18:08 AM
Fundamental Rating

3

Taking everything into account, CGEM scores 3 out of 10 in our fundamental rating. CGEM was compared to 536 industry peers in the Biotechnology industry. CGEM has a great financial health rating, but its profitability evaluates not so good. CGEM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CGEM had negative earnings in the past year.
In the past year CGEM has reported a negative cash flow from operations.
In the past 5 years CGEM reported 4 times negative net income.
In the past 5 years CGEM always reported negative operating cash flow.
CGEM Yearly Net Income VS EBIT VS OCF VS FCFCGEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of CGEM (-39.74%) is comparable to the rest of the industry.
CGEM's Return On Equity of -42.01% is fine compared to the rest of the industry. CGEM outperforms 70.90% of its industry peers.
Industry RankSector Rank
ROA -39.74%
ROE -42.01%
ROIC N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
CGEM Yearly ROA, ROE, ROICCGEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CGEM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGEM Yearly Profit, Operating, Gross MarginsCGEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CGEM has more shares outstanding
Compared to 5 years ago, CGEM has more shares outstanding
There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEM Yearly Shares OutstandingCGEM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGEM Yearly Total Debt VS Total AssetsCGEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CGEM has an Altman-Z score of 5.00. This indicates that CGEM is financially healthy and has little risk of bankruptcy at the moment.
CGEM's Altman-Z score of 5.00 is fine compared to the rest of the industry. CGEM outperforms 75.93% of its industry peers.
There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5
ROIC/WACCN/A
WACCN/A
CGEM Yearly LT Debt VS Equity VS FCFCGEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

CGEM has a Current Ratio of 9.83. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CGEM (9.83) is better than 80.41% of its industry peers.
A Quick Ratio of 9.83 indicates that CGEM has no problem at all paying its short term obligations.
The Quick ratio of CGEM (9.83) is better than 80.41% of its industry peers.
Industry RankSector Rank
Current Ratio 9.83
Quick Ratio 9.83
CGEM Yearly Current Assets VS Current LiabilitesCGEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

CGEM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.56%.
EPS 1Y (TTM)-5.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -5.38% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-24.12%
EPS Next 2Y-10.45%
EPS Next 3Y-3.46%
EPS Next 5Y-5.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGEM Yearly Revenue VS EstimatesCGEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
CGEM Yearly EPS VS EstimatesCGEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEM Price Earnings VS Forward Price EarningsCGEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEM Per share dataCGEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

CGEM's earnings are expected to decrease with -3.46% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.45%
EPS Next 3Y-3.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGEM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (10/3/2025, 11:18:08 AM)

5.95

+0.2 (+3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners101.87%
Inst Owner Change-3.01%
Ins Owners1.19%
Ins Owner Change0%
Market Cap351.47M
Analysts87.06
Price Target26.86 (351.43%)
Short Float %11.76%
Short Ratio12.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.24%
Min EPS beat(2)-25.93%
Max EPS beat(2)9.46%
EPS beat(4)3
Avg EPS beat(4)1.28%
Min EPS beat(4)-25.93%
Max EPS beat(4)16.07%
EPS beat(8)6
Avg EPS beat(8)8.34%
EPS beat(12)9
Avg EPS beat(12)8.34%
EPS beat(16)11
Avg EPS beat(16)4.94%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.66%
PT rev (3m)-8.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.63%
EPS NY rev (1m)0.29%
EPS NY rev (3m)-13.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-3.23
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.9
OCFYN/A
SpS0
BVpS8.33
TBVpS8.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.74%
ROE -42.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.83
Quick Ratio 9.83
Altman-Z 5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.88%
Cap/Depr(5y)267.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.67%
EPS Next Y-24.12%
EPS Next 2Y-10.45%
EPS Next 3Y-3.46%
EPS Next 5Y-5.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.17%
EBIT Next 3Y-1.73%
EBIT Next 5YN/A
FCF growth 1Y-5.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.32%
OCF growth 3YN/A
OCF growth 5YN/A